|Grant Number:||5R01CA098549-05 Interpret this number|
|Primary Investigator:||El-Zein, Randa|
|Organization:||Ut Md Anderson Cancer Ctr|
|Project Title:||Molecular Biomarkers as Predictors of Hodgkin's Disease|
DESCRIPTION (provided by applicant): A major concern for Hodgkin's Disease (HD) survivors is the development of recurrence or second primary tumors. Although factors responsible for the unfavorable outcomes and poor survival of HD patients remain incompletely understood, the population at highest risk seems to be genetically predisposed. In this proposal we propose to evaluate a panel of susceptibility biomarkers as predictors of disease outcome in an existing cohort of 254 HD patients for whom demographic, epidemiological, clinical data and pretreatment blood samples are available. We will test the hypothesis that unfavorable outcomes occur more frequently in patients with poor DNA repair capacity (measures by increase chromosome instability) and with adverse genotypes (polymorphisms in DNA repair and cell cycle control) as compared with patients with favorable outcome. Specifically we propose: 1) To collect follow-up information on health and vital status data to ascertain endpoints (recurrence or second primary tumors) for all the HD patients in the cohort; 2) To phenotypically characterize the role of background chromosomal instability (measured by chromosome aberrations and sister chromatid exchanges) in disease recurrence or development of SPTs. We hypothesize that patients with poor outcomes exhibit higher levels of baseline chromosomal damage than patients with favorable outcome. 3) To elucidate the role that specific polymorphisms in DNA repair capacity genes (XRCC1, XPD and XRCC3) and cell cycle control (p53 gene) play in the modulation of HD outcome. We hypothesize that individuals with DNA repair allelic variants have altered DNA repair capacity and increased risk of developing recurrence or SPT. Similarly, the allelic variants of p53 gene are associated with variant proteins that may alter cell cycle control encouraging progression either by inducing genomic instability and DNA misrepair or by permitting survival of mutants which will in turn have a negative impact on outcome; and 4) To analyze epidemiological and biomarker data independently and jointly as predictors of recurrence and development of SPTs. Identification of subgroups of HD patients who are at increased risk for recurrence or second primary tumor development has both clinical and prognostic relevance. The high risk population can be targeted for intensive preventive and early detection strategies.
Hodgkin lymphoma risk: role of genetic polymorphisms and gene-gene interactions in DNA repair pathways.
Authors: Monroy CM, Cortes AC, Lopez M, Rourke E, Etzel CJ, Younes A, Strom SS, El-Zein R
Source: Mol Carcinog, 2011 Nov;50(11), p. 825-34.
EPub date: 2011 Mar 3.
Variants in folate pathway genes as modulators of genetic instability and lung cancer risk.
Authors: Piskac-Collier AL, Monroy C, Lopez MS, Cortes A, Etzel CJ, Greisinger AJ, Spitz MR, El-Zein RA
Source: Genes Chromosomes Cancer, 2011 Jan;50(1), p. 1-12.
Rapid method for determination of DNA repair capacity in human peripheral blood lymphocytes amongst smokers.
Authors: El-Zein RA, Monroy CM, Cortes A, Spitz MR, Greisinger A, Etzel CJ
Source: BMC Cancer, 2010 Aug 18;10, p. 439.
EPub date: 2010 Aug 18.
Regulatory regions responsive to oxidative stress in the promoter of the human DNA glycosylase gene NEIL2.
Authors: Kinslow CJ, El-Zein RA, Rondelli CM, Hill CE, Wickliffe JK, Abdel-Rahman SZ
Source: Mutagenesis, 2010 Mar;25(2), p. 171-7.
EPub date: 2009 Nov 27.
Genetic polymorphisms in DNA repair genes as modulators of Hodgkin disease risk.
Authors: El-Zein R, Monroy CM, Etzel CJ, Cortes AC, Xing Y, Collier AL, Strom SS
Source: Cancer, 2009 Apr 15;115(8), p. 1651-9.
Cytokinesis-blocked micronucleus cytome assay biomarkers identify lung cancer cases amongst smokers.
Authors: El-Zein RA, Fenech M, Lopez MS, Spitz MR, Etzel CJ
Source: Cancer Epidemiol Biomarkers Prev, 2008 May;17(5), p. 1111-9.
Human sensitivity to PhIP: a novel marker for prostate cancer risk.
Authors: El-Zein R, Etzel CJ, Lopez MS, Gu Y, Spitz MR, Strom SS
Source: Mutat Res, 2006 Oct 10;601(1-2), p. 1-10.
EPub date: 2006 Aug 4.
Cytokinesis-blocked micronucleus assay as a novel biomarker for lung cancer risk.
Authors: El-Zein RA, Schabath MB, Etzel CJ, Lopez MS, Franklin JD, Spitz MR
Source: Cancer Res, 2006 Jun 15;66(12), p. 6449-56.
Evaluation of two different biomarkers for use in the assessment of toxic chemical exposure in California sea lions (Zalophus californianus).
Authors: El-Zein RA, Hastings-Smith DA, Ammenheuser MM, Treinen-Moslen M, Gulland FM, Ward JB Jr
Source: Mar Pollut Bull, 2006 Jan;52(1), p. 108-13.
EPub date: 2005 Nov 18.